Olav Dalgard

Olav Dalgard is a Professor II at Akershus University Hospital, affiliated with the Department of Internal Medicine and Laboratory Sciences. His work focuses on infectious diseases, particularly hepatitis C (HCV) and viral hepatitis, with an emphasis on treatment strategies, elimination efforts, and public health policy. He has led and contributed to numerous clinical trials evaluating antiviral therapies, including studies on direct-acting antivirals (DAAs) and their efficacy among high-risk populations such as people who inject drugs (PWID). His research spans epidemiology, virology, and healthcare policy, addressing challenges in HCV reinfection, treatment adherence, and global health equity. Notably, he has collaborated on large-scale initiatives like the NOR-Solidarity trial (assessing treatments for severe COVID-19) and the OPPORTUNI-C trial (optimizing HCV treatment in hospitalized PWID). His contributions also include analyzing antibiotic use in viral infections and evaluating outcomes of antiviral therapy withdrawal in chronic hepatitis B patients. Dalgard’s interdisciplinary approach bridges clinical practice, public health, and policy, aiming to improve global health outcomes through evidence-based interventions.